Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $10,430 | $13,518 | $31,185 | $39,599 |
| - Cash | $25,440 | $27,501 | $22,983 | $15,181 |
| + Debt | $41,203 | $40,939 | $40,671 | $40,425 |
| Enterprise Value | $26,193 | $26,956 | $48,873 | $64,843 |
| Revenue | $3,803 | $3,209 | $4,643 | $4,118 |
| % Growth | 18.5% | -30.9% | 12.7% | – |
| Gross Profit | $3,522 | $2,896 | $4,770 | $3,811 |
| % Margin | 92.6% | 90.2% | 102.7% | 92.5% |
| EBITDA | -$11,846 | -$16,420 | -$19,167 | -$21,308 |
| % Margin | -311.5% | -511.7% | -412.8% | -517.4% |
| Net Income | -$13,454 | -$18,030 | -$20,695 | -$22,784 |
| % Margin | -353.8% | -561.9% | -445.7% | -553.3% |
| EPS Diluted | -9.09 | -12.2 | -14.02 | -15.48 |
| % Growth | 25.5% | 13% | 9.4% | – |
| Operating Cash Flow | -$13,954 | -$14,554 | -$22,035 | -$24,005 |
| Capital Expenditures | -$1 | $0 | -$17 | -$216 |
| Free Cash Flow | -$13,955 | -$14,554 | -$22,052 | -$24,221 |